Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives $8.29 Average Target Price from Brokerages

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $8.29.

Several research firms recently commented on VTYX. Canaccord Genuity Group reduced their target price on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, August 12th. HC Wainwright reiterated a “neutral” rating and issued a $6.00 price objective on shares of Ventyx Biosciences in a report on Monday, September 23rd. Finally, Wells Fargo & Company cut their price objective on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 12th.

Ventyx Biosciences Stock Up 1.0 %

Ventyx Biosciences stock opened at $2.12 on Thursday. Ventyx Biosciences has a 52 week low of $1.79 and a 52 week high of $30.20. The business has a 50-day simple moving average of $2.16 and a 200 day simple moving average of $3.29. The stock has a market cap of $149.46 million, a price-to-earnings ratio of -0.65 and a beta of 0.36.

Ventyx Biosciences (NASDAQ:VTYX) last posted its earnings results on Thursday, August 8th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.12. On average, research analysts anticipate that Ventyx Biosciences will post -2.14 earnings per share for the current year.

Institutional Investors Weigh In On Ventyx Biosciences

Institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in Ventyx Biosciences during the 2nd quarter valued at about $32,000. The Manufacturers Life Insurance Company boosted its holdings in Ventyx Biosciences by 41.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after acquiring an additional 7,096 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Ventyx Biosciences during the 2nd quarter valued at about $58,000. Norden Group LLC purchased a new stake in Ventyx Biosciences during the 1st quarter valued at about $59,000. Finally, American Century Companies Inc. purchased a new stake in Ventyx Biosciences during the 2nd quarter valued at about $60,000. 97.88% of the stock is currently owned by hedge funds and other institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.